Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience

BACKGROUND: Induction therapy is used in about 80% of lung transplant centers and is increasing globally. Currently, there are no standards or guidelines for the use of induction therapy. At our institution, we have two induction strategies, basiliximab, and alemtuzumab. The goal of this manuscript...

Descripción completa

Detalles Bibliográficos
Autores principales: Furukawa, Masashi, Chan, Ernest G., Ryan, John P., Hyzny, Eric J., Sacha, Lauren M., Coster, Jenalee N., Pilewski, Joseph M., Lendermon, Elizabeth A., Kilaru, Silpa D., McDyer, John F., Sanchez, Pablo G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199390/
https://www.ncbi.nlm.nih.gov/pubmed/35720296
http://dx.doi.org/10.3389/fimmu.2022.864545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199390/
https://www.ncbi.nlm.nih.gov/pubmed/35720296
http://dx.doi.org/10.3389/fimmu.2022.864545

Ejemplares similares